Can gene therapies for haemophilia defend their high price tags?
Pharmaceutical Technology
NOVEMBER 9, 2022
million price tag. The post Can gene therapies for haemophilia defend their high price tags? After its approval, bluebird had set Zynteglo’s price at roughly EUR1.6 million ($1.8 million at the time). Since its FDA approval in August 2022, the beta-thalassemia therapy was launched in the US with a $2.8
Let's personalize your content